Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Dr. Lal Path Labs Ltd.

NSE: LALPATHLABHealthcare Service Provider

Share price

₹1,898.90

-2.38% close of 8 Oct 2026

Market cap ₹31,902 CrP/E 56.7

Business score

How strong the business is, in one number. The parts behind it are in Pro.

71

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹31,902 Cr

P/E ratio

56.7

P/B ratio

12.7

ROCE

28.0%

ROE

22.3%

Dividend yield

0.7%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹2,005.1052-week low ₹1,307.60

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 14.3% over the past year, and 13.6% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 24.7% to 28.9% over the last four years.

Whether it grew faster than its sector

It grew 13.6% a year against a sector median of 13.1% — 0.5 percentage points faster.

Room to re-rate, or risk of de-rating

At 56.7× earnings it costs 2.4× the market, which pays 23.9× across 2199 companies we can price. Its own industry sits at 51.6×, across 5 companies. It is against its own five-year median of 58.6×, the 43rd percentile of its own range.

Whether growth justifies the valuation

Priced at 1.9 times its growth rate, on earnings growth of 30%.

Profit growthPrice per ₹1 profitPer 1% growth
Dr. Lal Path Labs Ltd. — this one30%/yr56.7×₹1.9
Vijaya Diagnostic Centre Limited24%/yr76.5×₹3.2
Metropolis Healthcare Limited11%/yr51.6×₹4.7
Thyrocare Technologies Limited36%/yr44.3×₹1.2
Nephrocare Health Services Limited103%/yr73.7×—
Krsnaa Diagnostics Limited18%/yr17.5×₹0.97

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Healthcare Service Provider), it ranks 5 of 12 on returns, 8 of 11 on growth, 7 of 12 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A narrow advantage: it earns 28% on capital, ahead of 58% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹2643 crore of cash from the business, spent ₹801 crore on plant and equipment, and returned ₹1159 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 130 arrived as cash (before interest, which is why it can exceed the profit). Its cash comes back more slowly than it used to: it went from being paid 54 days before it paid its own suppliers to paid 29 days before it paid its own suppliers.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

9 of 9 checks clear · 100%

Latest result

What the last results showed. Whether management kept its word is in Pro.

Results are expected soon.

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹31,902 Cr
Prev close
₹1,898.90
52w High
₹2,039
52w Low
₹1,273
Enterprise value
₹30,768 Cr
Beta
0.5
Price CAGR 1y
26.0%
Price CAGR 3y
16.0%
Price CAGR 5y
1.0%
Price CAGR 10y
14.0%

Ratios

Return on assets
16.2%
PEG ratio
1.9
P/E ratio
56.7
P/B ratio
12.7
EV / EBITDA
36.7
Industry P/E
44.1
ROCE
28.0%
ROCE 5y average
25.8%
ROE
22.3%
Debt / Equity
0.1
Interest coverage
30.1
Dividend yield
0.7%
ROE 3y average
22.0%
ROE last year
22.0%

Annual P&L

Annual revenue
₹2,763 Cr
Annual profit
₹510 Cr
Operating margin
28.0%
Net profit margin
18.5%
EBITDA margin
28.3%
Sales growth 3y
11.1%
Sales growth 5y
11.8%
Profit growth 3y
30.0%
Profit growth 5y
12.0%
EPS
₹30.1
Sales growth TTM
14.0%
Profit growth TTM
10.0%
Dividend payout
68.0%

Quarter P&L

Sales latest quarter
₹798 Cr
Profit latest quarter
₹170 Cr
YoY quarterly sales growth
19.1%
YoY quarterly profit growth
26.9%
OPM latest quarter
31.0%

Balance Sheet

Book Value
₹149
Face Value
₹10.0
Total debt
₹199 Cr
Total cash
₹910 Cr
Borrowings
₹199 Cr
Reserves / Equity
13.9

Cash Flow

Operating cash flow
₹636 Cr
Free cash flow
₹463 Cr
FCF yield
1.4%
Net cash flow
-₹50 Cr

Shareholding

Promoter holding
53.2%
FII holding
17.4%
DII holding
21.6%
Public holding
7.5%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Dr Lal Pathlabs1,937.0057.832,5120.72170.528.0797.719.128.0
Vijaya Diagnost.1,465.0580.515,0900.1453.137.6231.022.820.5
Metropolis Healt542.0054.011,2440.3756.925.8450.216.617.8
Thyrocare Tech.511.1045.08,1351.8251.334.1240.024.335.4
Nephrocare Health Services631.7574.66,3530.0032.034.9281.823.715.3
Krsnaa Diagnost.538.4017.61,7460.3715.8-19.1210.719.912.7
Suraksha Diagno.318.0546.31,6560.1612.938.487.720.817.3
Median318.0533.71,1480.0011.028.095.219.120.5

Competes with: 3B Blackbio Dx Limited, Gaudium IVF and Women Health Limited, Health X Platform Limited, Krsnaa Diagnostics Limited, Metropolis Healthcare Limited, Molbio Diagnostics Limited, Nephrocare Health Services Limited, One Global Service Provider Limited, Pramodini Medicare Limited, Sastasundar Ventures Limited, Suraksha Diagnostic Limited, Thyrocare Technologies Limited, Vijaya Diagnostic Centre Limited

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales541601539545602660597603670731660703798
Expenses395424398401432458443434478506480516550
Material Cost118129142129135152
Change in Inventories000000
Purchases of Stock-in-Trade000000
Employee Cost115132132135129133
Other Expenses200216233217252266
Operating Profit146178141145170202154169192224179187248
OPM %27302627283126282931272731
Other Income14181818212225262825-62432
Exceptional items (within Other Income)000-3000
Interest8877665555766
Depreciation35363637353536363540424544
Profit before tax118152116120150183138153181204124160229
Tax %29272928282929-12625261725
Net Profit8411182861081319815613415291132170
EPS in Rs4.956.554.875.066.377.735.789.267.908.995.407.8410
Diluted EPS in Rs1916185.417.8510

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales6607919121,0571,2031,3301,5812,0872,0172,2272,4612,7632,891
Expenses5045826757939109871,1451,5261,5271,6171,7641,9792,053
Material Cost482535
Change in Inventories00
Purchases of Stock-in-Trade00
Employee Cost482503
Other Expenses802943
Operating Profit156210238264294344436561490609698783838
OPM %24262625242628272427282829
Other Income12202731465551524269917075
Exceptional items (within Other Income)0-30
Interest001111516303829222324
Depreciation28282833387377108150144142162172
Profit before tax140201237261301310394475344505625669717
Tax %313434343327252630282124
Net Profit96133156172200228296350241362492510546
EPS in Rs8.757.999.3110121417211421293032
Diluted EPS in Rs5830
Dividend Payout %9151622254457294204168

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
13%
5 years
12%
3 years
11%
TTM
14%

Compounded profit growth

10 years
15%
5 years
12%
3 years
30%
TTM
10%

Stock price CAGR

10 years
14%
5 years
1%
3 years
16%
1 year
26%

Return on equity

10 years
22%
5 years
21%
3 years
22%
Last year
22%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital5583838383838383838384168
Reserves2604255127058629491,1621,4181,5831,7662,0892,341
Borrowings2700000150533420247157199
Other Liabilities13411895128145341265309297357383433
Minority Interest3433
Total Liabilities4756256909161,0911,3741,6612,3432,3832,4542,7133,140
Fixed Assets1501661522082094134471,3691,3051,2281,1681,256
CWIP14181031110155637
Investments38641061451851645965150114327423
Other Assets2863914145546947861,1448939231,1071,2151,454
Total Assets4756256909161,0911,3741,6612,3432,3832,4542,7173,146

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity122159171197219284398447456535569636
Cash from Investing Activity-113-163-137-172-100-26-212-449-287-24-303-422
Cash from Financing Activity-10-3213-55-190-139136-283-414-334-264
Net Cash Flow8-5237646748134-11497-68-50
Free Cash Flow87115120125177205339-28412479516463

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days171717141614151513131315
Inventory Days373133444070393828302730
Days Payable908997106111144132107127151127123
Cash Conversion Cycle-35-42-47-47-55-60-78-54-87-108-86-79
Working Capital Days-92719170-19-26-54-56-46-30-29
ROCE %484743383532332918252928

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters555555555454545453535353
FIIs242526252727242222201717
DIIs8.859.279.40121313161818192122
Government0.290.290.290.290.290.290.290.290.270.010.010.01
Public11109.246.956.025.825.846.226.076.947.887.48
Others0.410.370.320.300.330.280.270.390.370.350.340.38
No. of Shareholders1,60,6791,49,9011,46,7411,31,1891,16,6061,16,2361,15,6991,18,6561,12,7031,16,1671,14,5271,11,037

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +23.0% (₹1,544.10 → ₹1,898.90)Brick size ₹63.04 (fixed)Bricks 15
₹1,400₹1,600₹1,800₹2,000₹1,899Dec '25Jul '26
Price moved up one brickPrice moved down one brickLast close ₹1,898.90 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

-1,134inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

50,85,670inr

2026-03-31

News

News and filings about Dr. Lal Path Labs Ltd.. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Chemicals
  • Laboratory supplies
  • Reagents
  • Surgicals

Buys from

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Healthcare Service Provider
Classification
Healthcare › Healthcare Service Provider
ISIN
INE600L01024

Plants

  • Kolkata Reference Laboratory · Kolkata, West Bengal
  • National Reference Laboratory · New Delhi, Delhi

News impact

Big market events that reach Dr. Lal Path Labs Ltd., and how the effect spreads.

24 Sept, 11:36 IST · Market event · high impact

Nephrocare shares tumble 5% | What’s driving the decline?

Large holders are selling about Rs 650 crore of kidney-care firm Nephrocare at a 5% discount, hurting current shareholders short-term while letting new buyers enter cheaper.

Healthcare

Who it hits first

  • Nephrocare Health Services, which runs kidney dialysis clinics, fell over 5% after reports that large holders want to sell about Rs 650 crore of shares at Rs 705 each.
  • That Rs 705 price is about 5% below the last close of Rs 741.90, so the market is repricing toward the cheaper deal price.
  • The business itself is unchanged — only the shareholding is shifting.

Who may gain

  • Buyers who get the block at Rs 705 gain an instant 5% discount to the Rs 741.90 close.
  • Patient investors who wanted Nephrocare shares can now buy the dip if the fall overdoes the discount.

Along the supply chain

Downstream

No direct downstream impact — hospitals it serves, including Max Healthcare, Fortis Healthcare, and Medanta, see no change to orders or contracts from this share sale.

Upstream

No direct supply-chain link upstream — Nephrocare lists no suppliers in the pack, and a shareholder sale does not change what it buys.

Where demand moves

Business

No change to patient visits, dialysis sessions, or clinic revenue — the Rs 650 crore sale moves existing shares between investors, not customers.

Capital

About Rs 650 crore of new share supply near Rs 705 pulls the price down short-term as traders sell; bargain hunters absorbing the block provide the offsetting buy flow.

How it spreads across sectors

Healthcare

No sector-wide impact — a single-company share sale with no change to hospital or lab demand; peers should trade flat.

When it plays out

Immediate

1–7 days: Nephrocare trades heavy near Rs 705 as the Rs 650 crore block clears; peers flat.

Medium term

1–6 months: price follows clinic results again, not the block; no lasting sector effect.

Short term

1–4 weeks: discount overhang fades if buyers hold; price stabilises unless more selling appears.

Who it hits first

  • Krsnaa Diagnostics won a 15-year Punjab government deal to run PET-CT cancer-imaging scans, opening a costly high-value scan business it did not have before.
  • The stock jumped 11% as investors priced in years of steady scan income from the long contract.

Who may gain

  • Krsnaa Diagnostics gains a 15-year revenue stream and a new high-value PET-CT line; no listed peer shares the award.

Along the supply chain

Downstream

Punjab government hospitals and patients get advanced cancer imaging locally instead of referring cases out.

Upstream

PET-CT scanners come from unlisted global makers (Siemens, GE, Philips) and tracer supply has no listed pure-play, so no listed upstream impact.

Where demand moves

Business

Punjab's public hospitals will send PET-CT scan demand to Krsnaa's new centres for 15 years; scanner makers and tracer suppliers are unlisted so no listed upstream benefit.

Capital

Money rotates into KRSNAA shares on the repricing; no sector-wide rotation since the award is exclusive to one company.

How it spreads across sectors

Healthcare

Mild positive: validates the PPP route for high-end diagnostics and hints other states may tender similar PET-CT deals.

When it plays out

Immediate

Shares already up 11%; follow-through depends on disclosed order value and rollout plan.

Medium term

Scan volumes and revenue/margin contribution from PET-CT over 1-6 months and beyond.

Short term

Agreement signing, centre commissioning schedule, and management commentary in quarterly results.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

30 Jul 2026interim₹5
25 Jun 2026unspecified₹4
5 Feb 2026interim₹3.5
19 Dec 2025bonus₹0
7 Nov 2025interim₹7
6 Aug 2025interim₹6
6 Jun 2025unspecified₹6
5 Feb 2025interim₹6

Splits, bonuses & buybacks

  • daily-prices repair: 9 rows from NSE's archive (replace 1, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Insider trades

DisclosedWhoTypeSharesValue ₹ Cr
30 Sep 2026Dr. Lal PathLabs Employee Welfare Trust · OtherSELL4,0500.39
30 Sep 2026Munender Soperna · Designated PersonBUY2,1000.20
30 Sep 2026Abhishek Maini · Designated PersonSELL7500.15
30 Sep 2026Abhishek Maini · Designated PersonBUY7500.09
25 Sep 2026Mrinal Kapoor · Designated PersonSELL2,0000.39
25 Sep 2026Dr. Lal PathLabs Employee Welfare Trust · OtherSELL3,0000.36
25 Sep 2026Sanjay Kulshreshtha · Designated PersonSELL1,5000.30
25 Sep 2026Mrinal Kapoor · Designated PersonBUY2,0000.25
25 Sep 2026Sanjay Kulshreshtha · Designated PersonBUY1,0000.12
21 Sep 2026Jai Prakash Meena · Designated PersonSELL4,5000.88

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.